Login to Your Account

Earnings Roundup

Production Woes on the Mend, But CVR Unlikely, Sanofi Says

By Jennifer Boggs

Friday, July 29, 2011
The consolidation of Genzyme Corp.'s operations into Sanofi SA helped the Paris-based big pharma firm offset generic threats to its revenue in the second quarter, but holders of Genzyme's contingent value rights (CVR) are unlikely to see the $1 CVR connected to manufacturing levels of enzyme replacement therapies (ERT) Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription